US Patent Issued to Health Research on Oct. 27 for "Major histocompatibility complex class II-expressing cancer cell vaccine and methods of use for producing integrated immune responses" (New York Inventors)

ALEXANDRIA, Va., Oct. 27 -- United States Patent no. 12,773,445, issued on Oct. 27, was assigned to Health Research Inc. (Buffalo, N.Y.).

"Major histocompatibility complex class II-expressing cancer cell vaccine and methods of use for producing integrated immune responses" was invented by Kunle Odunsi (Williamsville, N.Y.), Takemasa Tsuji (Williamsville, N.Y.) and Junko Matsuzaki (Williamsville, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are modified cancer cells that are modified to co-express class II trans-activator (CIITA), and an immuno-stimulatory molecule. The immuno-stimulatory molecule is OX-40-ligand or 4-IBB-Ligand. Methods of making the cells are provided by introducing polynucl...